C12N 2770/20033
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2770/20033 (Use of viral protein as therapeutic agent other than vaccine) appears on 14 US grants and 40 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 40
- Assignees
- 36
- Inventors
- 97
- Latest grant
- 8 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 2 |
| 2017 | 0 | 1 |
| 2018 | 1 | 1 |
| 2019 | 2 | 0 |
| 2020 | 0 | 0 |
| 2021 | 3 | 2 |
| 2022 | 2 | 5 |
| 2023 | 1 | 5 |
| 2024 | 1 | 12 |
| 2025 | 0 | 3 |
| 2026 | 3 | 8 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Exosomes comprising coronavirus-derived antigen protein or gene encoding same protein, and use of same8 Sep 2026US 12,728,154 B2Ewha University-Industry Collaboration Foundation
- Treatment regimen for the treatment of autoimmune disorders3 Feb 2026US 12,539,329 B2Merck Patent GmbH
- Treatment regimen for the treatment of autoimmune disorders27 Jan 2026US 12,533,408 B2Merck Patent GmbH
- Peptides for Covid-19 prevention and treatment16 Jul 2024US 12,037,363 B2Sotira Covid, LLC
- Peptides for the treatment of COVID-196 Jun 2023US 11,667,678 B2Rush University Medical Center
- Replicon dna, cloning vector, screening kit, screening method, anti-nobecov-irus agent, beta-coronavirus proliferation inhibitor, pan beta-coronavirus inhibitor, virus proliferation inhibitor, hepatitis c virus proliferation inhibitor, and method for screening therapeutic agent for viral infectious disease8 Oct 2026US 2026/0308206 A1Kagoshima University
- Method for constructing circular rna and vaccine against fipv21 May 2026US 2026/0137770 A1Beijing Syngentech Co., Ltd.
- Development of multi-antigen mrna vaccine against feline fipv21 May 2026US 2026/0137771 A1Beijing Syngentech Co., Ltd.
- Methods of treating lung cancer and other cancers by recombinant sars-cov-2 spike s121 May 2026US 2026/0139008 A1Rush University Medical Center
- Anti-Viral Therapeutic Peptides, Conjugates, and Methods of Use Thereof14 May 2026US 2026/0131011 A1Decoy Therapeutics Inc.
Most cited
By later US patents
- Peptides for Covid-19 prevention and treatment12US 11,078,242 B1Sotira Covid, LLC · 2021
- MERS-CoV inhibitor peptides4US 10,975,126 B1King Faisal University · 2021
- Anti-SARS-CoV-2 fusion peptides3US 11,479,582 B2King Faisal University · 2022
- Methods and compositions for eliciting an immune response against hepatitis B virus2US 9,452,212 B2Dynavax Technologies Corporation · 2016
- Methods and compositions for eliciting an immune response against hepatitis B virus1US 9,884,110 B2Dynavax Technologies Corporation · 2018